newsfilter
← Latest News
ACCESS Newswire·

LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities

BOCA RATON, FL / ACCESS Newswire / December 8, 2025 / In recent years, LIXTE has been defined by LB-100, its first-in-class PP2A inhibitor with a mechanism that unlocks new therapeutic angles for resistant